Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

NCT05863273 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.

NCT NCT05863273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05863273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）
Lead sponsor
First Hospital of China Medical University
Phase
Observational
Overall status
Completed
Start date
May 22, 2023
Completion date
March 10, 2025
Enrollment
360 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis